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Background: The role of chemotherapy in addition to combined endocrine therapy for premenopausal women with
endocrine-responsive early breast cancer remains an open question, yet trials designed to answer it have repeatedly
failed to adequately accrue. The International Breast Cancer Study Group initiated two concurrent trials in this
population: in Premenopausal Endocrine Responsive Chemotherapy (PERCHE), chemotherapy use is determined by
randomization and in Tamoxifen and Exemestane Trial (TEXT) by physician choice. PERCHE closed with inadequate
accrual; TEXT accrued rapidly.
Methods: From 2003 to 2006, 1317 patients (890 with baseline data) were randomly assigned to receive ovarian
function suppression (OFS) plus tamoxifen or OFS plus exemestane for 5 years in TEXT. We explore patient-related
factors according to whether or not chemotherapy was given using descriptive statistics and classification and
regression trees.
Results: Adjuvant chemotherapy was chosen for 64% of patients. Lymph node status was the predominant
determinant of chemotherapy use (88% of node positive treated versus 46% of node negative). Geography, patient
age, tumor size and grade were also determinants, but degree of receptor positivity and human epidermal growth
factor receptor 2 status were not.
Conclusions: The perceived estimation of increased risk of relapse is the primary determinant for using
chemotherapy despite uncertainties regarding the degree of benefit it offers when added to combined endocrine
therapy in this population.
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introduction
Chemotherapy, tamoxifen and ovarian function suppression/
ablation (OFS) are individually effective adjuvant treatments
for women <50 years of age with estrogen receptor
(ER)-positive breast cancer, as shown in several individual
trials and confirmed by meta-analyses [1–5]. For patients with
endocrine-nonresponsive disease, the effect of adjuvant
chemotherapy is independent of endocrine mechanisms [6, 7].
However, for endocrine-responsive [i.e. ER- and/or
progesterone receptor (PgR)-positive] breast cancer the
benefit of chemotherapy is due to a complex mixture of
cytotoxic and endocrine mechanisms. The additional
benefit of chemotherapy for premenopausal patients with
endocrine-responsive breast cancer who receive combined
endocrine treatment with OFS and tamoxifen (or an
aromatase inhibitor) remains an open question that
prospective randomized clinical trials have been unsuccessful
in answering, as diverging opinions regarding its efficacy
result in some physicians recommending it while others do
not [8].
In 1993, the International Breast Cancer Study Group
(IBCSG) activated a randomized clinical trial (IBCSG 11-93) to
investigate the role of adjuvant chemotherapy in
premenopausal patients with node-positive (N+), hormone
receptor-positive invasive breast cancer who receive combined
endocrine therapy with OFS and tamoxifen (Figure 1A) [9, 10].
o
ri
g
in
a
l
a
rt
ic
le
*Correspondence to: Dr M. M. Regan, IBCSG Coordinating Center, Effingerstrasse 40,
CH-3008 Bern, Switzerland. Tel: +41 31 389 93 91; Fax: +41 31 389 93 92;
E-mail: mregan@jimmy.harvard.edu
ª The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Patients were randomly allocated to receive four cycles
of adjuvant anthracycline-based chemotherapy plus long-term
OFS and 5 years of tamoxifen (initiated after chemotherapy) or
to receive the same combined endocrine therapy without
chemotherapy. From May 1993 to November 1998, 174
patients were randomized and the trial closed prematurely
because of the low accrual rate. Patients (median age 45 years)
tended to be at intermediate risk according to the St Gallen
Consensus Criteria [11], with 97% of patients having one to
three nodes involved. After a median follow-up of 10 years, 20
of the 89 patients randomized to chemotherapy plus OFS/
tamoxifen and 20 of 85 randomized to OFS/tamoxifen without
chemotherapy had relapsed; 12 patients had died of cancer in
each group. The estimated 10-year disease-free survival was
73% 6 5% for both groups (Hazard ratio = 1.02 for addition
of AC doxorubicin or epirubicin plus cyclophosphamide for 4
21-day cycles; 95% CI 0.57–1.83; P = 0.94) [10]. This trial,
although clearly underpowered, raises the question of whether
chemotherapy is needed in this intermediate-risk population
that received combined endocrine treatment [8].
In 2003, the IBCSG initiated a suite of three complementary
tailored treatment investigations, the Suppression of Ovarian
Function Trial (SOFT), Tamoxifen and Exemestane Trial
(TEXT) and Premenopausal Endocrine Responsive
Chemotherapy (PERCHE) trial, designed to answer questions
concerning adjuvant treatment for premenopausal women with
endocrine-responsive early breast cancer [12, 13]. The TEXT
and the PERCHE trials address two questions for women who
receive OFS from the start of adjuvant therapy. TEXT
(Figure 1C) investigates the role of aromatase inhibitors
compared with tamoxifen, and PERCHE (Figure 1B) the
value of adding chemotherapy to combined endocrine therapy.
These trials involve worldwide participation through the
Breast International Group (BIG) network and The Breast
Cancer Intergroup of North America.
In PERCHE, whether or not to use adjuvant chemotherapy
was determined by random assignment, whereas the oral
endocrine agent (tamoxifen or exemestane) combined with
OFS was determined by the participating center or by co-
enrollment in TEXT. The PERCHE trial had broader eligibility
criteria than its predecessor trial IBCSG 11-93 by including
patients with node-negative (N2) disease and allowing centers
to choose the chemotherapy regimen. Yet from August 2003 to
December 2006—at which point the trial was prematurely
closed to accrual—only 29 patients were enrolled in PERCHE
from 11 centers in seven countries (Australia, Canada,
Germany, Hungary, Italy, New Zealand, Switzerland), even
though there was widespread consensus among opinion leaders
that this was a pivotal study to prospectively determine the role
of chemotherapy in patients selected on the basis of clinical
criteria. Patients’ median age was 46 years (range 36–54 years).
Most patients had intermediate risk disease according to the
St Gallen Consensus Criteria [11], and had ER-positive and
PgR-positive tumors. Patients were equally divided as lymph
Figure 1. Trial designs for (A) International Breast Cancer Study Group (IBCSG) Trial 11-93, (B) Premenopausal Endocrine Responsive Chemotherapy
(PERCHE) trial and (C) Tamoxifen and Exemestane Trial (TEXT). All three trials are for premenopausal women with endocrine-responsive [estrogen
receptor (ER) and/or progesterone receptor (PgR) -positive] early breast cancer. Trial 11-93 was restricted to patients with node-positive disease.
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N2 and N+ disease, with all N+ having one to three
positive nodes. Twenty-five of 29 patients were co-enrolled
in TEXT.
TEXT has identical eligibility criteria to PERCHE, but the
trials have accrued at very different rates. PERCHE, which
randomly assigned whether or not to give chemotherapy,
accrued on average less than one patient per month. TEXT,
which randomly assigned the oral endocrine agent with the
center choosing whether to give chemotherapy for individual
patients, accrued >40 patients per month. It appears that
centers, generally physicians and possibly the patients as well,
prefer to make the decision of whether a patient will receive
chemotherapy and are unwilling to leave it to chance, but are
willing to let chance decide which oral endocrine agent to use.
The patients entered in TEXT provide an opportunity to
investigate what factors are used in the decision-making process
of whether or not to give chemotherapy in addition to
combined endocrine therapy in this patient population.
patients and methods
study design
TEXT (IBCSG 25-02) opened for accrual in August 2003 and was designed
to enroll 1845 premenopausal women with endocrine-responsive early
breast cancer (Figure 1C) who were randomly assigned to receive OFS plus
either tamoxifen (20 mg/day) or exemestane (25 mg/day) for 5 years. OFS
could be achieved by gonadotropin-releasing hormone (GnRH) analogue
(triptorelin 3.75 mg by intramuscular injection every 28 days) until 5 years
from randomization; bilateral surgical oophorectomy or bilateral ovarian
irradiation was allowed as an alternative after at least 6 months of GnRH
analogue. Randomization was stratified by whether or not chemotherapy
was planned. The chemotherapy regimen was the center’s choice but
a planned duration of ‡2 months was recommended if an anthracycline was
included or ‡4 months if no anthracycline was given. Patients receiving
chemotherapy commenced it after randomization, concurrently with the
GnRH analogue. Tamoxifen/exemestane started after adjuvant
chemotherapy was completed, if given, or 6–8 weeks after the initiation of
GnRH analogue, whichever was later.
The study required that randomization be within 12 weeks after
definitive surgery for histologically proven invasive breast cancer with
steroid hormone receptor-positive tumors, defined as ER and/or PgR
expression ‡10% of tumor cells by immunohistochemistry.
From 1 November 2003 to 31 December 2006—the period PERCHE was
also open to enrollment—1317 patients were enrolled in TEXT. The
analysis cohort was comprised of the 890 (68%) patients with complete
baseline case report forms in the database as of April 2007, and excluded the
25 patients who were co-enrolled in both TEXT and PERCHE. For both
trials, ethical boards of each participating center approved the protocols
and all patients provided written informed consent.
data and statistical considerations
Factors of interest included geographic region (cooperative group network
and country, with the United States divided into four census regions),
patient age, local–regional treatment plan (type of definitive surgery and
whether or not radiotherapy was planned) and locally assessed disease
characteristics [steroid hormone receptor status (negative for ER or PgR
versus positive for both), percentage of cells staining for ER and PgR
(among patients treated at institutions reporting this information), axillary
lymph node status (negative or positive as well as number of positive
nodes), tumor grade, tumor size, presence of peritumoral vascular invasion
(PVI) and human epidermal growth factor receptor 2 (HER2) status of the
tumor (considered as HER2 positive if amplified by FISH or 3+ by
immunohistochemistry and FISH not done)]. Patients were classified into
risk categories according to the 2005 St Gallen Consensus Criteria [11],
which consider patient age, number of positive lymph nodes, PVI and
tumor size, grade and HER2 status.
Descriptive statistics were presented, either as number and percent of
patients or as median, interquartile range (IQR) and range of values.
Classification and regression tree (CART) analysis [14] examined which
combination of factors best classified whether or not chemotherapy was
chosen, and investigated combinations of factors that identified groups of
patients in which a small or large proportion received chemotherapy. The
initial analysis included geographic region, patient age and disease
characteristics; a secondary analysis also included levels of hormone
receptor expression among the subset of patients with this information
available.
results
Among the population of premenopausal patients with
endocrine-responsive disease who were enrolled in TEXT and
would be receiving 5 years of combined endocrine therapy,
additional adjuvant chemotherapy was chosen for 813 of 1317
(62%) patients. Among the subset of 890 in the study cohort,
adjuvant chemotherapy was chosen for 569 (64%).
geography
Overall there was no substantial difference in the percentage of
patients in the chemotherapy stratum for BIG centers
compared with North American centers (62% versus 66%,
respectively) (Table 1). Chemotherapy was consistently given
more often to patients with lymph node-positive (N+) disease
regardless of geographic region. The proportions of patients
receiving chemotherapy, however, varied widely according to
region, ranging from 64% to 100% of those with N+ disease
and from 18% to 83% of those with lymph node-negative
(N2) disease. Among patients with N2 disease, only 31% from
European centers received chemotherapy compared with 52%
from North American centers.
patient age and local–regional treatment
Younger patients were more likely to receive chemotherapy
overall and in both lymph node status cohorts (Table 1). The
majority of patients who were treated with mastectomy plus
radiation therapy received chemotherapy.
disease
Chemotherapy was chosen for 88% of patients with N+ disease
compared with 46% with N2 disease. The proportion of
patients given chemotherapy increased as the number of
positive nodes increased, with nearly all patients having four or
more positive nodes receiving chemotherapy (Table 2). A clear
pattern emerged of choosing chemotherapy according to the
2005 St Gallen risk categories (Table 3) (19% versus 63% versus
96% of low- versus intermediate- versus high-risk patients,
respectively), yet the continued role of nodal status within the
intermediate category is also apparent (51% of
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N2 intermediate risk versus 83% of N+ intermediate risk).
The individual characteristics that comprise the St Gallen
criteria are consistent with the overall risk categorization
(Tables 3 and 4); patients with more aggressive disease
characteristics (presence of PVI, higher grade tumors, >2 cm
tumors, HER2-positive tumors) more often received
chemotherapy, a pattern particularly apparent among patients
with N2 disease.
All patients in TEXT had hormone receptor-positive tumors,
of whom only 11% had tumors negative for either ER or
PgR (1.5% ER negative and 9.5% PgR negative). Given the
caveat of small numbers, higher proportions of N2 patients
with either ER-negative or PgR-negative tumors received
chemotherapy, an observation not apparent in N+ disease
(Table 4). For 85% of patients, the continuous percentage of
ER and PgR immunostaining cells was reported; higher
proportions of patients in the N2 cohort with tumors
expressing very low levels (£20% expression) of either ER or
PgR received chemotherapy (Figure 2).
all factors
CART analysis explored which factors classified patients into
subgroups with low or high chemotherapy prescription. The
predominant factor was nodal status (Figure 3). Geographical
regions formed the next split for patients with both N2 and N+
disease. Among patients with N+ disease, two geographical
groupings emerged in which 72% versus 94% of patients
received chemotherapy, with patient age or presence of PVI as
further determinants among the two groupings, respectively.
Among patients with N2 disease, 32% versus 60% of patients
received chemotherapy in two geographical groupings. Among
countries choosing chemotherapy less frequently, tumor size
and patient age were determinants: patients with £1 cm tumors
Table 1. Chemotherapy use by geographic region, patient age and local–regional treatment plan, overall and according to patients’ lymph node status
Lymph node negative Lymph node positive All patients Total
No adj. CT Adj. CT No adj. CT Adj. CT No adj. CT Adj. CT
All patients 273 (54) 230 (46) 48 (12) 339 (88) 321 (36) 569 (64) 890
Geographical regiona
BIG 144 (61) 93 (39) 38 (16) 204 (84) 182 (38) 297 (62) 479
Belgium (2) 6 3 1 4 7 7 14
Germany (2) 3 2 0 1 3 3 6
Hungary (1) 12 (41) 17 (59) 4 (7) 52 (93) 16 (19) 69 (81) 85
Italy (10) 81 (74) 29 (26) 21 (27) 58 (73) 102 (54) 87 (46) 189
Slovenia (1) 4 0 0 1 4 1 5
Sweden (1) 0 0 0 2 0 2 2
Switzerland (8) 18 (82) 4 (18) 8 (36) 14 (64) 26 (59) 18 (41) 44
South Africa (1) 4 0 0 0 4 0 4
Peru (1) 2 (17) 10 (83) 1 (4) 27 (96) 3 (8) 37 (93) 40
Australia/New Zealand (17) 14 (33) 28 (67) 3 (6) 45 (94) 17 (19) 73 (81) 90
North American Intergroup 129 (48) 137 (52) 10 (7) 135 (93) 139 (34) 272 (66) 411
Canada (7) 22 (34) 43 (66) 0 (0) 41 (100) 22 (21) 84 (79) 106
United States (76) 107 (53) 94 (47) 10 (10) 94 (90) 117 (38) 188 (62) 305
Midwest (24) 47 (58) 34 (42) 1 (5) 19 (95) 48 (48) 53 (52) 101
Northeast (20) 27 (51) 26 (49) 4 (10) 38 (90) 31 (33) 64 (67) 95
South (18) 19 (45) 23 (55) 4 (13) 27 (87) 23 (32) 50 (68) 73
West (14) 14 (56) 11 (44) 1 (9) 10 (91) 15 (42) 21 (58) 36
Patient age (years)
Median [IQR] 45 [41–47] 43 [39–46] 46 [42–48] 42 [38–46] 45 [41–47] 43 [39–46] 43 [39–47]
<35 13 (33) 26 (67) 2 (5) 36 (95) 15 (19) 62 (81) 77
35–39 35 (51) 33 (49) 4 (5) 74 (95) 39 (27) 107 (73) 146
40–44 86 (50) 87 (50) 14 (11) 118 (89) 100 (33) 205 (67) 305
45–49 105 (60) 70 (40) 21 (18) 94 (82) 126 (43) 164 (57) 290
‡50 34 (71) 14 (29) 7 (29) 17 (71) 41 (57) 31 (43) 72
Local–regional treatmentb
Mastectomy, no RT 65 (53) 57 (47) 15 (15) 83 (85) 80 (36) 140 (64) 220
Mastectomy, with RT 5 (14) 32 (86) 3 (3) 96 (97) 8 (6) 128 (94) 136
LTM with RT 203 (59) 141 (41) 30 (16) 160 (84) 233 (44) 301 (56) 534
Number (%) unless otherwise specified. Percentages sum across the row and are not provided for small numbers.
aNumber of centers within the country or region that have randomized patients are given in parenthesis.
bRadiation therapy was mandated by protocol for patients treated with less than mastectomy.
Adj., adjuvant; CT, chemotherapy; BIG, Breast International Group; IQR, interquartile range; RT, radiation therapy; LTM, less than mastectomy.
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least frequently received chemotherapy (13%), whereas
patients aged £43 years having >1 cm tumors most frequently
received chemotherapy (71%). In the countries where
chemotherapy was chosen for 60% of patients with N2 disease,
tumor grade, size and patient age were determinants. The
factors that did not appear to play a major role in decision
making were ER status, PgR status or HER2 status of the
tumor, neither did the continuous percentage of ER and PgR
immunostaining cells appear to play a role in the reanalysis
among the subset of patients for whom these percentages were
available.
discussion
Clearly there is a group of patients with low to intermediate risk
of relapse after surgery for early breast cancer for whom
chemotherapy adds little or no benefit to combined endocrine
therapy, but the oncology community has not been able to
recruit to randomized trials designed to investigate this
question despite multiple attempts. The premature closure of
PERCHE, and of IBCSG Trial 11-93 10 years earlier, because of
inadequate accrual demonstrates that when treating
premenopausal endocrine-responsive early breast cancer,
physicians and/or patients are not willing to allow random
chance to decide whether or not to give chemotherapy. Indeed,
the 2007 St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer [15] described the
selection of whether to give chemotherapy for patients with
endocrine-responsive disease ‘perhaps the most difficult
decision in current adjuvant therapy’, mainly because there are
only underpowered clinical trial results to aid in this decision.
The current absence of sufficient information also challenges
decisions to prematurely close trials due to low accrual, with
the reason for doing so being that the scientific question will
not be relevant long term. However, 10 years after the closure
of IBCSG Trial 11-93 the question addressed remains
unanswered, and there is no trial planned for the foreseeable
future.
We investigated characteristics of patients enrolled in TEXT,
where the decision of whether or not to use chemotherapy
was determined not by the trial, but at the center, and observed
that positive lymph node status was the predominant
determinant of chemotherapy choice. Strong geographical
patterns were observed also, indicating regional biases, but in
spite of preconceived ideas, the United States did not use more
chemotherapy in N2 populations compared with several other
countries. The fact that nodal status was most often used to
make the decision reflects a perceived increase in risk of
recurrence on the basis of years of research and clinical trials
that divided breast cancer patients on the basis of staging.
Geographical differences may arise from a variety of sources,
including institutional guidelines, national health advisories,
insurance coverage, experience with agents such as GnRH
Table 2. Chemotherapy use by tumor characteristics
All patients Total
No adj. CT Adj. CT
Number of patients 321 (36) 569 (64) 890
Node–positive axillary LN
0 273 (54) 230 (46) 503
1–3 43 (16) 234 (84) 277
4–9 2 (3) 68 (97) 70
10+ 0 (0) 32 (100) 32
Unknown 3 5 8
St Gallen risk categoriesa
Low 67 (81) 16 (19) 83
Intermediate 244 (37) 407 (63) 651
Intermediate N2 203 (49) 211 (51) 414
Intermediate N+ 41 (17) 196 (83) 237
High 5 (4) 137 (96) 142
Number (%). Percentages sum across the row.
aFourteen patients could not be completely classified because of missing
pathology data.
Adj., adjuvant; CT, chemotherapy; LN, lymph nodes.
Table 3. 2005 St Gallen risk categories [15] (Definition of risk categories
for patients with operated breast cancer)
Risk catetory
Low riska Node negative AND all of the following features:
pT £2 cm, AND
Grade 1b, AND
Absence of peritumoral vascular invasionc, AND
HER2/neu gene neither overexpressed nor
amplifiedd, AND
Age ‡35 years
Intermediate riske Node negative AND at least one of the
following features:
pT >2 cm, OR
Grade 2–3,b OR
Presence of peritumoral vascular invasionc, OR
HER2/neu gene overexpressed or amplifiedd, OR
Age <35 years
Node Positive (1–3 involved nodes) AND
HER2/neu gene neither overexpressed
nor amplifiedd
High risk Node positive (1–3 involved nodes) AND
HER2/neu gene overexpressed or amplifiedd
Node positive (4 or more involved nodes)
aSome Panel members view pTla and pTlb (i.e. pT<1 cm) tumors with
node-negative disease as representing low risk even if higher grade and/or
younger age.
bHistologic and/or nuclear grade.
cPeritumoral vascular invasion was considered controversial as
a discriminatory feature of increased risk; its presence defined intermediate
risk for node-negative disease, but did not influence risk category for node-
positive disease.
dHER2/neu gene overexpression or amplification must be determined by
quality-controlled assays using immunohistochemistry or fluorescence
in situ hybridization analysis.
eNote that the intermediate-risk category includes both node-negative and
node-positive 1–3 disease.
pT, pathological tumor size (i.e, size of the invasive component).
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analogues, local opinion leaders’ positions and other factors.
Randomized clinical trials that remove biases in the perceived
value of chemotherapy in the absence of direct evidence of its
benefit, however, have been unsuccessful.
Overall, overview analyses and analyses of individual trials
have demonstrated a significant benefit for adjuvant
chemotherapy compared with no chemotherapy, especially for
premenopausal women [1–4]. These analyses have several
limitations such as using age <50 years as a proxy for
premenopausal status, including a combination of patients with
endocrine-responsive and -nonresponsive tumors and
sometimes with no hormone receptor assessment, and using
possibly less than optimal endocrine treatments. The National
Surgical Adjuvant Breast and Bowel Project B-20 trial
demonstrated benefit of combination chemotherapy with
cyclophosphamide, methotrexate and fluorouracil in addition
to tamoxifen versus tamoxifen alone for premenopausal
women with endocrine-responsive N2 disease [16]. In the
recent meta-analysis of adjuvant luteinizing hormone-releasing
hormone agonists [5], the addition of OFS plus tamoxifen
for patients who receive chemotherapy was beneficial in
endocrine-responsive disease with a 26.7% relative reduction in
risk of recurrence (95% CI, 38.7% to 12.3% risk reduction;
P = 0.001). This meta-analysis, however, did not address the
question of adding chemotherapy for patients receiving optimal
endocrine treatment (the PERCHE question). IBCSG Trial
11-93 [9, 10], which investigated the addition of chemotherapy
to combined OFS plus tamoxifen in a small group of patients
(n = 174), has shown neither benefit from adding
chemotherapy nor an indication of a detrimental effect on
disease control by avoiding chemotherapy. IBCSG Trial 11-93
continues to be the only published study on the role of adding
chemotherapy among premenopausal patients with N+
endocrine-responsive disease who receive combined endocrine
therapy with OFS plus tamoxifen. This question will become
even more important if the results of the ongoing SOFT
demonstrate benefit for the addition of OFS to tamoxifen as
adjuvant therapy in premenopausal women.
The 2005 St Gallen Consensus endorsed endocrine
responsiveness as the primary disease characteristic to consider
Table 4. Chemotherapy use by tumor characteristics, overall and according to patients’ lymph node status
Lymph node negative Lymph node positive All patients Total
No Adj. CT Adj. CT No Adj. CT Adj. CT No Adj. CT Adj. CT N
All patients 273 (54) 230 (46) 48 (12) 339 (88) 321 (36) 569 (64) 890
Tumor size (cm)
£1 83 (78) 24 (22) 8 (24) 25 (76) 91 (65) 49 (35) 140
1.1–2 152 (56) 119 (44) 20 (14) 121 (86) 172 (42) 240 (58) 412
>2 37 (31) 84 (69) 19 (10) 180 (90) 56 (18) 264 (83) 320
Unknown 1 3 1 13 2 16 18
Tumor grade
1/well 82 (69) 37 (31) 17 (23) 58 (77) 99 (51) 95 (49) 194
2/moderate 159 (56) 127 (44) 23 (13) 161 (88) 182 (39) 288 (61) 470
3/poorly 27 (30) 63 (70) 7 (6) 110 (94) 34 (16) 173 (84) 207
Unknown 5 3 1 10 6 13 19
Peritumoral vascular invasion
No 229 (58) 168 (42) 31 (20) 124 (80) 260 (47) 292 (53) 552
Yes 37 (42) 52 (58) 13 (6) 197 (94) 50 (17) 249 (83) 299
Unknown/not assessed 7 (41) 10 (59) 4 (18) 18 (82) 11 (28) 28 (72) 39
HER2 statusa
Negative 246 (58) 179 (42) 44 (13) 282 (87) 290 (39) 461 (61) 751
Positive 22 (31) 48 (69) 3 (6) 48 (94) 25 (21) 96 (79) 121
Unknown 5 3 1 9 6 12 18
ER/PgR status
ER2/PgR+ 0 (0) 8 (100) 1 (13) 7 (88) 1 (6) 15 (94) 16
ER+/PgR2 14 (35) 26 (65) 6 (13) 39 (87) 20 (24) 65 (76) 85
ER+/PgR+ 259 (57) 196 (43) 41 (12) 290 (88) 300 (38) 486 (62) 786
Unknown/missing 0 0 0 3 0 3 3
ER%, median (IQR)b 85 (70–90) 80 (67–95) 80 (70–90) 80 (70–90) 85 (70–90) 80 (70–90) 80 (70–90)
PgR%, median (IQR)b 80 (50–90) 75 (30–90) 80 (40–90) 70 (25–90) 80 (50–90) 70 (30–90) 75 (37–90)
Number (%) unless otherwise specified. Percentages sum across the row.
aHER2 positive if amplified by FISH, or immunohistochemistry (IHC) 3+ and FISH not done.
bPatients were required to have ER-positive and/or PgR-positive tumors, with positive defined as ‡10% immunostaining cells by IHC; quantitative levels
were available for 719 (ER) and 715 (PgR) patients.
Adj., adjuvant; CT, chemotherapy; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; PgR, progesterone
receptor.
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for selection of adjuvant systemic therapy [11], and the 2007
Consensus reaffirmed and refined this position [15]. The
endocrine effects of chemotherapy in young women are also
well documented [17], indicating the need to tailor therapies
according to their relative endocrine and cytotoxic effects. The
2007 St Gallen Consensus [15] panelists accepted either
tamoxifen plus OFS or tamoxifen alone as standard endocrine
therapies for premenopausal patients. In premenopausal
women with endocrine-responsive disease and a low or
intermediate risk of recurrence on average, it is possible that
a benefit equivalent to that obtained by chemotherapy plus
tamoxifen may be achieved by a combination of OFS plus
tamoxifen (or possibly an aromatase inhibitor).
Additional biologic factors such as HER2 expression/
amplification and/or measures of proliferation might identify
patients with endocrine-responsive disease who possibly derive
less benefit from endocrine therapy [18]. Several recent studies
have indicated that gene expression profiling can distinguish
patient subsets deriving different benefit from endocrine
treatment and chemotherapy [19–22]. In our analysis,
Figure 2. Chemotherapy use according to estrogen receptor (ER) expression level (top panel) and progesterone receptor (PgR) expression level (bottom
panel) of the tumor by immunohistochemistry, according to patients’ lymph node status. Expression (x-axis) is divided into 20% bins; the table provides the
numbers of patients in each bin.
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biological characteristics which may help determine the degree
of endocrine responsiveness of the tumor such as ER and PgR
expression levels and HER2 status did not appear to be major
determinants of chemotherapy choice.
The Microarray In Node-negative Disease may Avoid
ChemoTherapy (MINDACT) and Trial Assigning
IndividuaLized Options for Treatment (Rx) (TAILORx) trials
were launched in 2006 for women with early-stage breast cancer
with the objective of validating the utility of signatures of
molecular or gene expression profiles in clinical practice
[23, 24]. The trials focus on the question of whether these
signatures identify a subset of patients with operable N2 breast
cancer who may not need chemotherapy. Neither trial will be
able to address the question posed in the PERCHE trial, for
reasons including the lack of statistical power to examine the
premenopausal subgroup and the lack of standardized
endocrine therapy, the choice of which may be influenced by
whether or not the patient is amenorrheic after chemotherapy.
The role of adjuvant chemotherapy, in addition to optimal
endocrine therapy, for premenopausal breast cancer patients
with endocrine-responsive disease, and in particular those
with limited or no nodal involvement, remains unclear. The
inability to directly address the question was once again
evidenced by the closure of the PERCHE trial after enrolling
only 29 patients over a period of more than 3 years. We
conclude that the perceived estimation of increased risk of
relapse is the primary determinant for using chemotherapy
despite uncertainties regarding whether it offers benefit (or
degree of benefit) when added to combined endocrine therapy
for patients with endocrine-responsive disease.
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Oncology, Division of Pathology, Milan, Italy: G. Viale.
Quality of Life Office: J. Bernhard, K. Ribi, D. Gerber.
Breast International Group
International Breast Cancer Study Group: Australian New
Zealand Breast Cancer Trials Group (ANZ BCTG)—ANZ
BCTG Operations Office, Newcastle, Australia: J. Forbes,
D. Lindsay (Head of Data Management), H. Badger (Team
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Hospital, Coffs Harbour, New South Wales, Australia:
K. Briscoe; Liverpool Hospital, Liverpool, New South Wales,
Australia: S. Della-Fiorentina; Macarthur Cancer Therapy
Centre, Campbelltown, New South Wales, Australia: S. Della-
Fiorentina; Calvary Mater Newcastle, Newcastle, New South
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Wagga Wagga, New South Wales, Australia: J. Hill;
Tamworth Rural Referral Hospital, Tamworth, New South
Wales, Australia: D. Goldstein; Tweed Hospital, Tweed
Heads, New South Wales, Australia: E. Abdi; Royal Brisbane
and Women’s Hospital, Brisbane, Queensland, Australia:
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Australia, Australia: B. Koczwara; Launceston General
Hospital, Launceston, Tasmania, Australia: I. Byard; Royal
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Egypt: H. Khaled.
Hungary—National Institute of Oncology, Budapest,
Hungary: I. La´ng.
Italy—Azienda Ospedaliero-Universitaria di Udine, Udine,
Italy: F. Puglisi; Centro di Riferimento Oncologico, Aviano,
Italy: D. Crivellari; Fondazione Salvatore Maugeri, Pavia,
Italy: L. Pavesi; Istituto Europeo di Oncologia, Milano, Italy:
M. Colleoni, A. Goldhirsch; Ospedale degli Infermi, Rimini,
Italy: A. Ravaioli; Ospedale di Circolo e Fondazione Macchi,
Varese, Italy: G. Pinotti; Ospedali Riuniti di Bergamo,
Bergamo, Italy: C. Tondini; Sandro Pitigliani Medical Oncology
Unit, Hospital of Prato, Prato, Italy: A. Di Leo; Spedali Civili,
Brescia, Italy: E. Simoncini; Unita Operativa de Medicina
Oncologica, Ospedale Ramazzini, Carpi, Italy: F. Artioli.
Peru—Instituto de Enfermedades Neopla´sicas, Lima,
Peru: H. Gomez.
Slovenia—Institute of Oncology, Ljubljana, Slovenia: B. Pajk.
South Africa—Groote Schuur Hospital and University of
Cape Town, Cape Town, South Africa: E. Murray.
Sweden—West Swedish Breast Cancer Study Group:
S. B. Holmberg; Sahlgrenska University Hospital, Go¨teborg,
Sweden: P. Karlsson.
Switzerland—Swiss Association for Clinical Cancer Research:
R. Herrmann; Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland: K. Zaman; Inselspital, Berne,
Switzerland: S. Aebi; Institute of Oncology of Southern
Switzerland: O. Pagani (Ospedale San Giovanni, Bellinzona;
Ospedale Regionale di Lugano (Civico & Italiano), Lugano;
Ospedale Regionale Beata Vergine, Mendrisio; Ospedale
Regionale La Carita`, Locarno; Istituto Cantonale di Patologia,
Locarno); Kantonsspital St Gallen, St Gallen, Switzerland:
B. Thu¨rlimann; Ra¨tisches Kantonos-/Regionalspital, Chur,
Switzerland: R. von Moos; University Hospital Basel, Basel,
Switzerland: C. Rochlitz.
German Exemestane Adjuvant Group
Germany—Caritas-Krankenhaus St Josef, Regensburg,
Germany: O. Ortmann; Mammazentrum, Klinikum
Deggendorf, Deggendorf, Germany: D. Augustin; St Vincentius
Kliniken Karlsruhe, Karlsruhe, Germany: H.-G. Meerpohl.
North America
American College of Surgeons Oncology Group—Hope,
A Women’s Cancer Center, Asheville, NC: D. J. Hetzel.
Cancer and Leukemia Group B—Dana-Farber Cancer
Institute, Boston, MA: H. J. Burstein; Massachusetts General
Hospital, Boston, MA: H. J. Burstein; Faulkner Hospital,
Boston, MA: H. J. Burstein; Emerson Hospital, Concord, MA:
H. J. Burstein; Addison Gilbert, Gloucester, MA: A. P.
McIntyre; Mountainview Medical, Burlington, VT: S. Burdette-
Radoux; University of Vermont, Burlington, VT: S. Burdette-
Radoux; University of Maryland Greenebaum Cancer Center,
Pottstown, PA: K. H. Rak Tkaczuk; University of Chicago,
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Chicago, IL: G. F. Fleming; Walter Reed Army Medical Center,
Dayton, OH: T. J. A. Reid; Fort Wayne Medical Oncology/
Hematology, Inc., Ft Wayne, IN: S. R. Nattam; Northern
Indiana Research Consortium, South Bend, IN: R. H. Ansari;
Hematology Oncology Associates/Quad Cities, Bettendorf,
IA: S. R. Chitneni; Margaret R. Pardee Memorial Hospital,
Hendersonville, NC: J. E. Radford; Greenville Community
Clinical Oncology Program (CCOP), Greenville, SC:
J. K. Giguere; Washington University School of Medicine,
St Louis, MO: M. J. C. Ellis; University of California at
San Francisco, San Francisco, CA: H. S. Rugo; University of
California at San Diego, San Diego, CA: J. E. Mortimer.
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Portsmouth, NH: E. M. Bonnem; United Hospital, St Louis
Park, MN: P. J. Flynn; San Francisco General, San Francisco,
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Deaconess Medical Center, Boston, MA: H. J. Burstein; Tufts-
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Albert Einstein College of Medicine, Bronx, NY: C. M.
Pellegrino; Montefiore Medical Center, Bronx, NY: C. M.
Pellegrino; Our Lady of Mercy Medical Center, Bronx, NY: P.
H. Wiernik; New York University Medical Center, New York,
NY: A. D. Tiersten; Hackensack University Medical CCOP,
Hackensack, NJ: R. J. Rosenbluth; Virtua West Jersey Hospitals,
Mt Holly, NJ: M. S. Entmacher; South Jersey Hospital System,
Vineland, NJ: D. H. Blom; Frederick Memorial Hospital,
Frederick, MD: B. M. O’Connor; Aultman Health Foundation,
Canton, OH: J. A. Schmotzer Jr; Evanston Northwestern
Healthcare, Evanston, IL: D. E. Merkel; Metro-Minnesota
CCOP, St Louis Park, MN: P. J. Flynn; Aspirus Wausau
Hospital Center, Wausau, WI: U. Gautam; Via Christi Regional
Medical Center, Wichita, KS: S. R. Dakhil; West Virginia
University, Morgantown, WV: J. Abraham; Erlanger Medical
Center, Chattanooga, TN: L. L. Schlabach; University of Miami
Sylvester Cancer Center, Miami, FL: S. Gluck, J. Hurley;
Comprehensive Cancer Care Specialist at Boca Raton, Boca
Raton, FL: I. Wiznitzer, E. Kruglyak.
North Central Cancer Treatment Group—Allan Blair Cancer
Center, Regina, Saskatchewan, Canada: M. Salim; Saskatoon
Cancer Center, Saskatoon, Saskatchewan, Canada: S. Amer;
Mayo Clinic, Rochester, MN: J. N. Ingle, M. Goetz, E. A. Perez;
Mayo Clinic Jacksonville, Jacksonville, FL: J. N. Ingle,
E. A. Perez, M. P. Goetz; Saint Mary’s Medical Center,
Ann Arbor, MI: P. J. Stella; Medcenter One Health Systems,
Bismarck, ND: E. J. Wos; Billings Clinic, Billings, MT:
B. T. Marchello; Geisinger Medical Center, Danville, PA:
A. M. Bernath Jr; Oncology-Hematology Associates of
Central Illinois, Peoria, IL: J. W. Kugler; Siouxland
Hematology-Oncology Associates, Sioux City, IA:
D. B. Wender; Sioux Valley Clinic-Oncology, Sioux Falls,
SD: L. K. Tschetter; Saint John’s Hospital, Springfield,
MO: J. W. Goodwin; Metro-Minnesota CCOP, St Louis Park,
MN: P. J. Flynn; United Hospital, St Louis Park, MN: P. J. Flynn.
National Cancer Institute of Canada—Tom Baker Cancer
Center, Calgary, Alberta, Canada: B. A. Walley; Cross Cancer
Institute, Edmonton, Alberta, Canada: K. S. Tonkin; Hospital
Charles LeMoyne, Greenfield Park, Quebec, Canada: C. Prady;
Juravinski Cancer Centre at Hamilton Health Sciences,
Hamilton, Ontario, Canada: R. G. Tozer; Trillium Health
Center, Mississauga, Ontario, Canada: J. A. Gapski; Saskatoon
Cancer Center, Saskatoon, Saskatchewan, Canada: S. Amer.
The National Surgical Adjuvant Breast and Bowel Project
Mercy Medical Center, Baltimore, MD: D. A. Riseberg; Suburban
Hospital, Bethesda, MD: C. B. Hendricks; Frederick Memorial
Hospital, Frederick, MD: B. M. O’Connor; Mission Hospitals,
Inc., Asheville, NC: M. J. Messino; Moses H. Cone Memorial,
Greensboro, NC: J. E. Feldmann; Presbyterian Hospital,
Charlotte, NC: R. B. Reiling; Margaret R. Pardee Memorial
Hospital, Hendersonville, NC: J. E. Radford; Forsyth Memorial
Hospital, Winston-Salem, NC: J. O. Hopkins; Greenville
CCOP, Greenville, SC: J. K. Giguere; Saint Louis University
Hospital, St Louis, MO: P. J. Petruska, John H. Stroger Jr;
Hospital of Cook County, Chicago, IL: K. A. Dookeran; North
Idaho Cancer Center, Coeur D’Alene, ID: H. Tezcan; Desert
Regional Medical Center, Palm Springs, CA: C. G. Leichman;
Sutter Community Hospital, Sacramento, CA: V. Caggiano;
University of California Medical Center at Irvine, Orange, CA:
R. S. Mehta.
Southwest Oncology Group—Moses H. Cone Memorial,
Greensboro, NC: J. E. Feldmann; Greenville CCOP, Greenville,
SC: J. K. Giguere; Northeast Georgia Medical Center,
Gainesville, GA: R. J. LoCicero; William Beaumont Hospital,
Royal Oak, MI: D. Zakalik; Kansas City CCOP, Kansas City,
MO: W. T. Stephenson; University of Arkansas, Little Rock,
AR: L. F. Hutchins; University of Colorado, Aurora,
CO: A. D. Elias; Montana Cancer Consortium CCOP, Billings,
MT: P. W. Cobb; Saint Luke’s Mountain States Tumor
Institute, Boise, ID: T. A. Walters; Stormont-Vail Regional
Health Center, Topeka, KS: S. J. Vogel; Cancer Center of
Kansas-Medical Arts Tower, Wichita, KS: S. R. Dakhil; Cancer
Center of Kansas-Wichita, Wichita, KS: S. R. Dakhil; Via
Christi Regional Medical Center, Wichita, KS: S. R. Dakhil;
Doctor’s Hospital of Laredo, Laredo, TX: G. W. Unzeitig;
Swedish Hospital Medical Center, Seattle, WA: S. E. Rivkin;
Madigan Army Medical Center, Tacoma, WA: D. E. McCune;
Saint Joseph Medical Center, Burbank, CA: R. L. Friedman,
R. R. Mena; Presbyterian Hospital, Whittier, CA:
J. H. Freimann Jr.
Radiation Therapy Oncology Group—North Shore Cancer
Center, Peabody, MA: K. J. Krag; Aultman Health Foundation,
Canton, OH: J. A. Schmotzer Jr.
Participants in Trial IBCSG 26-02/BIG 4-02/
PERCHE—Peter MacCallum Cancer Centre, Melbourne,
Victoria, Australia: P. Francis; Tweed Hospital, Tweed Heads,
New South Wales, Australia: E. Abdi; Auckland Hospital,
Auckland, New Zealand: V. Harvey; National Institute of
Oncology, Budapest, Hungary: I. La´ng; Centro di Riferimento
Oncologico, Aviano, Italy: D. Crivellari; Istituto Europeo di
Oncologia, Milano, Italy: M. Colleoni, A. Goldhirsch;
Azienda Ospedaliero-Universitaria di Udine, Udine, Italy:
F. Puglisi; Kantonsspital St Gallen, St Gallen, Switzerland:
B. Thu¨rlimann; Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland: K. Zaman; Caritas-Krankenhaus
St Josef, Regensburg, Germany: O. Ortmann; Hospital
Charles LeMoyne, Greenfield Park, Quebec, Canada:
C. Prady.
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